- CA$29.16m
- CA$26.44m
- CA$17.93m
Annual balance sheet for NexgenRx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.32 | 1.77 | 1.88 | 1.71 | 4.78 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.479 | 0.41 | 0.778 | 0.874 | 0.725 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 20.8 | 18 | 23.3 | 24.7 | 32.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.504 | 0.835 | 0.809 | 0.826 | 0.799 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 29.4 | 25.7 | 30.2 | 30.5 | 36.6 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 19.6 | 16.5 | 22.1 | 22.4 | 28.7 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Liabilities | 19.7 | 16.9 | 22.5 | 22.8 | 29 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 9.71 | 8.85 | 7.71 | 7.62 | 7.62 |
| Total Liabilities & Shareholders' Equity | 29.4 | 25.7 | 30.2 | 30.5 | 36.6 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |